Advertisement

Annals of Surgical Oncology

, Volume 18, Issue 12, pp 3353–3361 | Cite as

Survival Factors in Patients with Recurrence After Curative Resection of Esophageal Squamous Cell Carcinomas

  • Hiroshi Miyata
  • Makoto Yamasaki
  • Yukinori Kurokawa
  • Shuji Takiguchi
  • Kiyokazu Nakajima
  • Yoshiyuki Fujiwara
  • Koji Konishi
  • Masaki Mori
  • Yuichiro Doki
Gastrointestinal Oncology

Abstract

Background

Approximately half of patients who undergo curative resection for esophageal cancers develop recurrence postoperatively. The factors affecting survival after such recurrence remain largely unknown.

Methods

To investigate factors affecting survival after recurrence in patients who had undergone curative resection for esophageal cancer, we retrospectively reviewed data for 461 patients who underwent curative esophagectomy with or without preoperative therapy for esophageal squamous cell carcinoma from January 1996 to December 2007. The correlations between several clinicopathological factors and survival after recurrence were examined.

Results

Recurrence occurred in 196 of 461 patients (42.5%), with a median survival time after recurrence of 8.2 months. Multivariate analysis identified advanced tumor stage, preoperative chemoradiotherapy (CRT), number of recurrent tumors, and the presence of recurrence at the local site and liver as associated with shortened survival after recurrence. The analysis also indicated that treatment of the recurrence prolonged survival regardless of the treatment type. Although the pattern of recurrence did not significantly differ according to type of preoperative therapy, patients who underwent preoperative CRT were less often treated with radiotherapy for recurrence. Patients with multiple recurrent tumors less often received radiotherapy or surgery than those with a solitary recurrence. Chemotherapy for recurrence was not associated with either preoperative therapy or the number of recurrences.

Conclusions

Our retrospective study showed that multiple recurrent tumors and preoperative CRT limit the available treatment for recurrence and thereby are associated with poor prognosis. Vigorous treatment for recurrence can extend survival after recurrence in patients who undergo esophagectomy.

Keywords

Esophageal Cancer Esophageal Squamous Cell Carcinoma Recurrent Disease Curative Resection Preoperative Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Altorki n, Skinner D. Should en block esophagectomy be the standard care for esophageal carcinoma? Ann Surg. 2001;234:581–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994;220:364–72.PubMedCrossRefGoogle Scholar
  3. 3.
    Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two field lymphadenectomy. Br J Surg. 2000;87:1426–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Hulscher JB, van Sandick JW, Tijssen JG, Obertop H, van Lanschot JJ. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg. 2000;191:143–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Bhansali MS, Fujita H, Kakegawa T, Yamana H, Ono T, Hikita S, et al. Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg. 1997;21:275–81.PubMedCrossRefGoogle Scholar
  7. 7.
    Chen G, Wang Z, Liu XY, Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg. 2007;31:1107–14.PubMedGoogle Scholar
  8. 8.
    Mariette C, Balon JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003;97:1616–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Matsubara T, Ueda M, Takahashi T, Nakajima T, Nishi M. Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus. J Am Coll Surg. 1996;182:340–6.PubMedGoogle Scholar
  10. 10.
    Doki Y, Ishikawa O, Takachi K, Miyashiro I, Sasaki Y, Ohigashi H, et al. Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma. World J Surg. 2005;29:700–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.PubMedCrossRefGoogle Scholar
  13. 13.
    Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet. 2002;359:1727–33.CrossRefGoogle Scholar
  15. 15.
    Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for respectable esophageal cancer. Am J Surg. 2002:183; 274–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Miyata H, Yano M, Doki Y, Yasuda T, Yoshioka S, Sugita Y, et al. A prospective trial for avoiding cervical lymph node dissection for thoracic esophageal cancers, based on intra-operative genetic diagnosis of micrometastasis in recurrent laryngeal nerve chain nodes. J Surg Oncol. 2006;93:477–84.PubMedCrossRefGoogle Scholar
  17. 17.
    Yoshioka S, Fujiwara Y, Sugita Y, Okada Y, Yano M, Tamura S, et al. Real-time rapid reverse transcriptase-polymerase chain reaction for intraoperative diagnosis of lymph node micrometastasis: clinical application for cervical lymph node dissection in esophageal cancers. Surgery. 2002;132:34–40.PubMedCrossRefGoogle Scholar
  18. 18.
    Yano M, Shiozaki H, Tsujinaka T, Inoue M, Doki Y, Fujiwara Y, et al. Squamous cell carcinoma of the esophagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy. J Am Coll Surg. 2000;191:626–34.PubMedCrossRefGoogle Scholar
  19. 19.
    Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y, et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer. 2009;115:3324–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Japanese Society for Esophageal Diseases. Guidelines for the clinical and pathologic studies on carcinoma of the esophagus. 10th ed. Tokyo, Japan: Kanehara Syuppan; 2007.Google Scholar
  21. 21.
    Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Hölscher A, Law S, et al. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008;248:979–85.PubMedCrossRefGoogle Scholar
  22. 22.
    Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Hofstetter W, Correa AM, Bekele N, Ajani JA, Phan A, Komaki RR, et al. Proposed modification of nodal status in AJCC esophageal cancer staging system. Ann Thorac Surg. 2007;84:365–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Nishimura Y, Koike R, Nakamatsu K, Kanamori S, Suzuki M, Shigeoka H, et al. Concurrent chemoradiotherapy with protracted infusion of 5-FU and cisplatin for postoperative recurrent or residual esophageal cancer. Jpn J Clin Oncol. 2003;33:341–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Baxi SH, Burmeister B, Harvey JA, Smithers M, Thomas J. Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review. J Med Imaging Radiat Oncol. 2008;52:583–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Yamashita H, Nakagawa K, Tago M, Nakamura N, Shiraishi K, Ohtomo K. Salvage radiotherapy for postoperative loco-regional recurrence of esophageal cancer. Dis Esophagus. 2005;18:215–20.PubMedCrossRefGoogle Scholar
  27. 27.
    Nemoto K, Ariga H, Kakuto Y, Matsushita H, Takeda K, Takahashi C, et al. Radiation therapy for loco-regionally recurrent esophageal cancer after surgery. Radiother Oncol. 2001;61:165–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Osugi H, Takemura M, Higashino M, Takada N, Lee S, Ueno M, et al. Cause of death and pattern of recurrence after esophagectomy and extended lymphadenectomy for squamous cell carcinoma of the thoracic esophagus. Oncol Rep. 2003;10:81–7.PubMedGoogle Scholar
  29. 29.
    Lerut T, Moons J, Coosemans W, Van Raemdonck D, De Leyn P, Decaluwé H, et al. Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification. Ann Surg. 2009;250:798–807.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Hiroshi Miyata
    • 1
  • Makoto Yamasaki
    • 1
  • Yukinori Kurokawa
    • 1
  • Shuji Takiguchi
    • 1
  • Kiyokazu Nakajima
    • 1
  • Yoshiyuki Fujiwara
    • 1
  • Koji Konishi
    • 2
  • Masaki Mori
    • 1
  • Yuichiro Doki
    • 1
  1. 1.Department of Gastroenterological Surgery, Graduate School of MedicineOsaka UniversityOsakaJapan
  2. 2.Radiation Oncology, Graduate School of MedicineOsaka UniversityOsakaJapan

Personalised recommendations